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G-protein-coupled receptors (GPCRs) constitute the most populated family of proteins within the human genome. Since the early
sixties work on GPCRs and on GPCR-mediated signaling has led to a number of awards, the most recent being the Nobel Prize in
Chemistry for 2012.The future of GPCRs research is surely based on their capacity for heteromerization. Receptor heteromers offer
a series of challenges that will help in providing success in academic/basic research and translation into more effective and safer
drugs.
1. Introduction
Soon in his career, Dr. R. Franco started working with the
so-called G-protein-coupled receptors (GPCRs), also known
as heptaspanning or serpentine receptors (see below). The
“G proteins” coupled to these receptors are called “het-
erotrimeric” as they are composed of three subunits: 𝛼, 𝛽, and
𝛾. A very good way to present these receptors is found in the
press release for the Nobel Prize in Chemistry for 2012. The
awarded scientists were Robert J. Lefkowitz from the Howard
Hughes Medical Institute and Duke University Medical Cen-
ter, Durham, NC, USA, and Brian K. Kobilka from Stanford
University School of Medicine, Stanford, CA, USA. The
complete press release (from http://www.nobelprize.org/)
was as follows.
Smart Receptors on Cell Surfaces. Your body is a fine-tuned
system of interactions between billions of cells. Each cell has tiny
receptors that enable it to sense its environment, so it can adapt
to new situations. Robert Lefkowitz and Brian Kobilka are
awarded the 2012 Nobel Prize in Chemistry for groundbreaking
discoveries that reveal the inner workings of an important
family of such receptors: G-protein-coupled receptors.
For a long time, it remained a mystery how cells could
sense their environment. Scientists knew that hormones such as
adrenalin had powerful effects: increasing blood pressure and
making the heart beat faster. They suspected that cell surfaces
contained some kind of recipient for hormones. But what these
receptors actually consisted of and how they worked remained
obscured for most of the 20th century.
Lefkowitz started to use radioactivity in 1968 in order to
trace cells’ receptors. He attached an iodine isotope to various
hormones, and, thanks to the radiation, he managed to unveil
several receptors, among those was a receptor for adrenalin:
𝛽-adrenergic receptor. His team of researchers extracted the
receptor from its hiding place in the cell wall and gained an
initial understanding of how it works.
The team achieved its next big step during the 1980s. The
newly recruited Kobilka accepted the challenge to isolate the
gene that codes for the 𝛽-adrenergic receptor from the gigantic
human genome.His creative approach allowed him to attain his
goal. When the researchers analyzed the gene, they discovered
that the receptorwas similar to one in the eye that captures light.
They realized that there is a whole family of receptors that look
alike and function in the same manner.
Today this family is referred to as G-protein-coupled
receptors. About a thousand genes code for such receptors,
for example, for light, flavour, odour, adrenalin, histamine,
dopamine, and serotonin. About half of all medications achieve
their effect through G-protein-coupled receptors.
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The studies by Lefkowitz and Kobilka are crucial for
understanding how G-protein-coupled receptors function. Fur-
thermore, in 2011, Kobilka achieved another breakthrough; he
and his research team captured an image of the 𝛽-adrenergic
receptor at the exact moment that it is activated by a hormone
and sends a signal into the cell. This image is a molecular
masterpiece—the result of decades of research.
This paper is written according to what an Outlook in
Scientifica aims to be, that is, a brief review (with limited
amount of references) on a number of closely related projects
in a specific laboratory (in this particular case a laboratory
that has been working for years in GPCRs) and a forward-
looking analysis of the issues that authors believe will drive
future research on the specific field and topic. The paper
is written with a historical perspective that may help in
understanding the advances in the GPCR heteromer field.
2. Adenosine, Adenosine Deaminase, and
Adenosine Receptors
The smart receptors chosen back in 1985 at theDepartment of
Biochemistry of the University of Barcelona were adenosine
receptors and the reason is simple. First of all, R. Franco did
his Ph.D. studying the purine metabolic enzymes in brain
and one of the most important findings was the ectoenzyme
nature of adenosine deaminase [1] that was later proven
from blood cells [2] to neurons [3]. The enzyme removes
extracellular adenosine, which is there (extracellularly) to
activate cell surface adenosine receptors. However, a stay in
the laboratory of Professor G. Burnstock, at the University
College of London at that time, was needed to notice that
GPCRs were worth being devoted a scientific career. It
is true that Professor Burnstock’s interests were more on
knowing molecular aspects of ATP neurotransmission, but
ATP receptors were for a young scientist a big challenge. It
was safer to opt for investigating the more modest adenosine
receptors for which good tool compounds (agonists and
antagonists) started to be available. Tool compounds for ATP
receptors have been much more difficult to obtain and, also,
ATP receptors can be ionotropic (P2X) and metabotropic
(P2Y) and there are a total of about 20 different subtypes
plus a significant number of splice variants [4]. Adenosine
receptors are only four and few splice variants have been
described and/or characterized. In the eighties adenosine
receptors were divided into two: the one whose activation
leads to increases in cAMP (A
1
) and the one that leads
to decreases in cAMP (A
2
) [5]. Different pharmacological
profiles among A
2
receptors led to postulate the existence of
two different A
2
receptors: A
2A and A2B [6, 7]. When many
GPCRs were cloned, four different adenosine receptors were
identified and named as follows: A
1
, A
2A, A2B, and A3.
3. G-Protein-Coupled Receptors Also Interact
with Other Proteins
Definition of GPCRs as coupled to G protein is somewhat
misleading as the receptors may bind other proteins and G-
protein-independent events also happen upon GPCR acti-
vation. In the Molecular Neurobiology Laboratory of the
University of Barcelona, a number of proteins were identified
as able to interact with the A
1
, A
2A, and/or A2B receptors.
To the surprise of all scientists in the whole laboratory,
one of them was adenosine deaminase, which is routinely
added to all assays to get rid of endogenous adenosine.
The ectoenzyme nature of adenosine deaminase (ADA1) was
confirmed by Kameoka et al. [8], who reported that an
activation lymphocyte marker, CD26, was able to bind ADA1
on the cell surface [9]. On the one hand, extracellular ADA1,
including that circulating in the blood, may bind to a variety
of membrane proteins (adenosine receptors [10–12] and
CD26). On the other hand, the binding of the enzyme that
degrades a neuromodulator or neurohormone, adenosine, to
an adenosine receptor posed a conceptual problem. Different
experimental approaches led to showing that the interaction
of the two proteins confers high affinity for adenosine, that
is, that low concentration of adenosine leads to efficient
A
1
receptor activation. At higher concentrations ADA is no
longer interacting with the receptor that in turn becomes
refractory to the compound. Further work ended up with
a nice model by which ADA1 may act as a bridge between
two cells, one displaying CD26 and the other displaying A
1
receptors.
ADA1 is a protein whose deficit leads to severe combined
immunodeficiency. It may bind not only to CD26 and
A
1
adenosine receptors but also to A
2A or A2B adenosine
receptors. Pacheco et al. [13] reported that ADA1 “enhanced
T cell proliferation in autologous co-cultures with antigen-
pulsed immature or mature dendritic cells. They also showed
a 3-fold reduction in the EC50 for the antigen by the action
of ADA1.” Furthermore, costimulation was not due to the
enzymatic activity but to the interaction of ADA-CD26
complexes in T cells. In fact ADA1 acted as a bridge by a dual
interaction, with adenosine receptors expressed on dendritic
cells and with CD26 expressed on lymphocytes. This cell-
to-cell communication facilitated by ADA1 constitutes an
important component in the immunological synapse and
leads to a marked increase in the production of diverse and
physiologically relevant cytokines [14]. For other adenosine-
receptor-interacting proteins that were identified in our
laboratory, see the following: Sarrio´ et al. [15]; Burguen˜o et
al. [16]; Canela et al. [17]; Franco et al. [18, 19].
4. Homodimers and Homooligomers
Starting around the mid-nineties, the focus of the Molecular
Neurobiology Laboratory has been devoted to understand
why many GPCRs, adenosine receptors included, form
dimers and even higher-order structures. With exceptions,
homodimers seem to be the most predominant form of
GPCRs on the cell surface, which is where the receptor
meets the hormone/neurotransmitter [20].The occurrence of
homodimers instead of monomers may not be relevant from
a physiological point of view. In fact monomers of receptors
may signal, at least in artificial membranes able to incor-
porate GPCRs. Whorton et al. [21] developed high-density
lipoprotein phospholipid bilayer particles containing beta2-
adrenergic receptors and the stimulatory heterotrimeric G
protein, Gs. A monomeric adrenergic receptor molecule
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Figure 1: Cartoon showing that cooperation between different receptors may achieve objectives that are unobtainable for a single receptor.
In a tribute to one of the names used for these receptors (serpentine receptors) they are depicted as serpents/snakes; each colored serpentine
would correspond to a given GPCR. The fruits and the fruit tree are a pictorial metaphor of cell/biological functions that may be reached by
activation of GPCR monomers, dimers, or trimers. Copyright is retained by N. Franco.
may activate Gs and display GTP-sensitive allosteric ligand-
binding properties thus suggesting that a monomeric recep-
tor is the minimal functional unit necessary for signaling in
a lipid bilayer.
It should be noted thatmetabotropic glutamate receptors,
which belong to another subfamily of GPCRs-class C-, tend
to form homodimers in which a ligand binds to one of the
protomers, but the dimer signals through the G protein that
is coupled to the second protomer [22]. It may occur that a
given G protein sits below a dimer but in asymmetrical form,
that is, having the𝛼 subunit of theGprotein close to one of the
protomers but not to the other. In any case the occurrence of
dimers may be irrelevant if one’s focus is a given receptor and
a given signaling pathway.However dimers open a completely
new pharmacological field that helps to analyze data and
interpret them. For instance, radioligand binding of agonists
to the A
1
receptor leads to two different affinities. Classically
they have been considered high- and low-affinity forms of the
receptor, the high-affinity one assumed to be due to the G-
protein-receptor complex and the low-affinity one assumed
to be due to the receptor (without the G protein). As dimers
have two different binding sites, one in each protomer, it
might be that each binding site has its own affinity for a given
ligand; in other words, the binding of the firstmolecule to one
of the protomers may lead to conformational changes in the
dimer that affects the binding to the second (empty) binding
site. Drs. Enric I. Canela andVicent Casado´ were able to build
up the two-state dimer model and develop the tools for fitting
binding data to receptor dimers. The model is simpler than
that assuming the occurrence of receptor with and without G
proteins and made predictions that were demonstrated in in
vitro assays [23, 24].
5. Intramolecular Conformational Changes
The phenomenon of ligand-driven conformational changes
in oligomeric proteins, that is very familiar for enzymol-
ogists and protein biochemists and is known by them as
“cooperativity,” is now incorporated into pharmacology. As
hemoglobin needs to be constituted by 4 protomers to
provide advantages to mammals, GPCRs may need to form
dimers or higher-order oligomers for optimal biological
performance. To understand whether homooligomers have
advantages over monomers is however not an easy task. The
task is a bit easier when considering heteromers.
6. Heterodimers and Heterooligomers
Advance on understanding the biology of GPCR heteromers
is nowadays a challenge in the field and the main objective in
the laboratory. The work ahead is straightforward and needs
to respond to an apparent simple question, which is the added
value of heteromers in nature. It should be noted that to
convince scientists of the occurrence of such heteromers has
not been an easy task. Fortunately there is now consensus [25]
on the presence of heteromers in almost every cell in every
tissue.
7. Added Value of Heteromers
From work in different laboratories it becomes clear that
GPCR heteromers confer selective advantages. Whereas
monomeric (even homomeric) receptor operation is mono-
tone, heteromeric receptor operation is multiple and varied.
Figure 1 displays a cartoon showing the advantages of recep-
tor cooperation due to heteromerization. Structurally GPCRs
have seven transmembrane domains with extracellular and
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intracellular loops connecting them, plus the extracellular
N terminal domain and a cytoplasmic C terminal tail. Due
to this particular structure, these receptors are also known
as heptaspanning or serpentine receptors. The abbreviation
“sr” for serpentine is being used for the subfamilies (sra,
srb, etc.) of the numerous chemosensory GPCR receptors in
Caenorhabditis elegans [26]. This is the reason for displaying
GPCRs in Figure 1 as serpents.
A few examples of heteromer-directed function, coming
from the work in the Laboratory of Susan George (University
of Toronto) and from that in the University of Barcelona,
will be here provided. The D
1
dopamine receptor subtype
is coupled to Gs proteins, that is, to proteins that mediate
increases in cAMP. In contrast, the D
2
subtype is coupled to
Gi proteins, which mediate decreases in cAMP. Interestingly
D
1
-D
2
receptor heteromers do not couple with Gs or Gi but
with Gq, which trigger calcium mobilization. These results
are important as they show that a single neurotransmitter,
dopamine, may lead to changes in cAMP in D
1
-receptor-
containing neurons or D
2
-receptor-containing neurons or
to increases in intracellular calcium in neurons that con-
tain D
1
-D
2
receptor heteromers. A single neurotransmitter
may thus trigger three different responses in three different
cells or, eventually, in three different subcellular locations
of the same cell. Dopamine D
1
and D
2
receptors are the
most abundant dopaminergic receptors in the striatum, and
although a clear segregation between the pathways expressing
these two receptors has been reported in certain subregions,
the presence of D
1
-D
2
receptor heteromers occurs within a
unique subset of neurons; in these cells heteromers form a
novel signaling transducing functional entity. Recently, sig-
nificant progress has been made in elucidating the signaling
pathways activated by the D
1
-D
2
receptor heteromers and
their potential physiological relevance [27]. In fact the Gq-
mediated signaling cascade may be activated in adult rat
brain, although with regional specificity (largely limited to
the nucleus accumbens). This specific dopaminergic pathway
seems to regulate brain-derived neurotrophic factor effects on
neuronal growth and maturation, thus having considerable
interest in disorders such as drug addiction, schizophrenia,
and depression [28, 29]. May dopamine via, for instance, D
2
receptor, trigger a further response? Indeed it is possible as it
has been shown that these receptors may form trimers with
A
2A receptor and with cannabinoid CB1 receptors and that
their activation engages another heteromer-specific signaling
pathway [30, 31].
A different example is that constituted by the A
1
-A
2A
receptor heteromers, which arise as a sensor of the con-
centration of extracellular adenosine. Ciruela et al. [32]
demonstrated that heteromerization of adenosineA
1
andA
2A
receptors allows adenosine to exert a fine-tuning modula-
tion of glutamatergic neurotransmission. Using a convergent
approach using coimmunoprecipitation, bioluminescence,
and time-resolved fluorescence resonance energy transfer
techniques, A
1
-A
2A receptor heteromers were detected in the
cell surface of cotransfected cells. Immunogold detection and
coimmunoprecipitation experiments indicated that A
1
and
A
2A are colocalized in the same striatal glutamatergic nerve
terminals. Radioligand-binding experiments in cotransfected
cells and rat striatum showed that a main biochemical
characteristic of the A
1
-A
2A heteromers is the ability of A2A
receptor activation to reduce the affinity of theA
1
receptor for
agonists. Overall the heteromer provides a switchmechanism
by which low and high concentrations of adenosine inhibit
and stimulate, respectively, glutamate release.
Interestingly the A
1
-A
2A receptor heteromers are also
expressed in astrocyte populations [33]. Astrocytes play a
key role in modulating synaptic transmission by controlling
extracellular gamma-aminobutyric acid (GABA) levels via
GAT-1 and GAT-3 GABA transporters. Using primary cul-
tures of rat astrocytes, Cristo´va˜o-Ferre´ira et al. [33] showed
that a further level of regulation of GABA uptake occurs
by activation of adenosine receptors in the A
1
-A
2A receptor
heteromers. Adenosine regulation of GABA uptake occurs
via two different G proteins, Gs and Gi/o, and the nucleoside
either enhances (A
2A) or inhibits (A1) GABA uptake. Again
an opposite regulation is possible by just one molecule,
adenosine, and acts on A
1
-A
2A receptor heteromers. This
would not be possible if neurons or astrocytes express A
1
or
A
2A or a combination of A1 and A2A receptors. The charac-
teristics of the A
1
-A
2A receptor heteromers are unique and
do not merely result from the addition of two independent
receptor-mediated signals.
8. Heteromers in Natural Tissues and in
Human Disease
AbdAlla et al. [34] were the first to link GPCR heteromers
and disease; they suggested that angiotensin 1-bradykinin 2
receptor heterodimers contribute to angiotensin II hypersen-
sitivity in preeclampsia. Thereafter not many other disorders
have been associated with altered G-protein-coupled recep-
tor heteromerization. Understanding the factors regulating
heteromer expression and whether pathological conditions
affect heteromer expression are important challenges in the
GPCR heteromer field. There are still difficulties in knowing
whether heteromers are present in natural tissues. Until
recently, heteromers in natural sources could be detected by
looking for a fingerprint. For instance, synthetic radioligand
binding to a receptor in a given heteromer is usuallymodified
if the partner receptor is occupied by a selective synthetic
ligand. A novel and powerful technique is now available and
consists of detecting heteromers in slices from natural tissues
using specific antibodies and an appropriate amplification
approach. The technique is known as in situ proximity
ligation assay. Very recently we have shown that heteromers
are expressed in nonhuman primate (Macaca fascicularis)
striatum and in the 1-metil-4-fenil-1,2,3,6-tetrahidropiridina-
(MPTP-) primate model of Parkinson’s disease [35]. By
using the in situ proximity ligation assay and by iden-
tification of a radioligand-based fingerprint, A
2A-CB1-D2
receptor heteromers were found in the caudate-putamen
of na¨ıve and MPTP-treated animals. Interestingly, L-3,4-
dihydroxyphenylalanine (L-DOPA) treatment blunted the
biochemical fingerprint and led to weak heteromer expres-
sion; these findings constitute the first evidence of altered
receptor heteromer expression due to therapy and suggest
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that drugs specifically targeting A
2A-CB1-D2 receptor het-
eromersmay be successful in either normalizing basal ganglia
output or preventing L-DOPA-induced side effects.
9. Heteromers as Potential Targets in
Human Therapy
GPCRs have been successful as targets for human therapy.
Adenosine receptors in general and A
1
and A
2A receptors
in particular are potential targets for a variety of diseases,
from arrhythmias [36, 37] to Alzheimer’s disease [38]. As
these receptors may form heteromers, it is time to think
about heteromers themselves as potential targets. For sure
(see Section 8) heteromers are present in parkinsonian
conditions; it is therefore evident that current drugs are
targeting these heteromers; that is, L-DOPA treatment in
parkinsonian patients is targeting dopamine receptors both
in “monomeric” and “heteromeric” form. The possibility to
differentially target some heteromers and not others is very
attractive (see below). Not very often the binding of the
endogenous hormone/neurotransmitter affects the binding
of the endogenous hormone/neurotransmitter in the partner
receptor. In contrast, synthetic ligands may preferentially
target a given receptor in the conformation of a particular
heteromer. At present heteromer-selective compounds have
been mainly found by serendipity and/or by testing already
existing molecules in different heteromeric contexts. The
future will tell whether screening for heteromer-selective
compoundswill be commonpractice in pharmaceutical com-
panies and/or in medicinal chemistry laboratories. A couple
of approaches to facilitate screening for heteromers based
on time-resolved fluorescence resonance energy transfer are
currently being tested in the Laboratory of the University of
Barcelona.
10. Targeting Pre- or Postsynaptic Heteromers
Striatal adenosine A
2A receptors are highly expressed in
medium spiny neurons of the one of the two main basal
ganglia circuits (the indirect efferent pathway), where they
heteromerize with dopamine D
2
receptors; A
2A receptors
are also localized presynaptically in corticostriatal gluta-
matergic terminals contacting medium spiny neurons of the
second efferent pathway (the direct pathway), where they
heteromerize with adenosine A
1
receptors [39, 40]. It has
been hypothesized that presynaptic A
2A receptor antagonists
could be beneficial in dyskinetic disorders (Huntington’s
disease) while postsynaptic A
2A receptor antagonists may be
useful in Parkinson’s disease. On checking whether selective
A
2A receptor antagonists may be subdivided according to a
preferential pre- versus postsynaptic mechanism of action,
Orru et al. [41] reported that two antagonists, SCH-442416
and KW-6002, had a significant preferential pre- and post-
synaptic profile, respectively, while other tested compounds
(MSX-2, SCH-420814, ZM-241385, and SCH-58261) showed
no clear preference. By radioligand-binding experiments
performed in cells expressing A
2A-D2 or A1-A2A receptors,
it is possible to show that heteromerization plays a key role
in the presynaptic profile of SCH-442416, which binds with
much less affinity to A
2A receptors when coexpressed with
D
2
than when coexpressed with A
1
receptors. KW-6002
showed better relative affinity for A
2A receptors coexpressed
with D
2
receptors than coexpressed with A
1
receptors, which
can at least partially explain the postsynaptic profile of this
compound. Also, the in vitro pharmacological profile of
MSX-2, SCH-420814, ZM-241385, and SCH-58261 was in
accordance with their mixed pre- and postsynaptic profile.
These results pave the way to develop preferential pre- versus
postsynaptic actions or vice versa. In the case of A
2A receptor
antagonists, this heteromer-selective screening would lead
to either antidyskinetic or antiparkinsonian drugs. It should
be noted that in 2013 KW-6002 (istradefylline) has been
approved in Japan as antiparkinsonian agent (sold asNouriast
by Kyowa Hakko Kirin Co., Ltd.). The compound reduces
dyskinesia resulting from long-term treatment with classical
drugs such as L-DOPA see http://www.kyowa-kirin.com for
further information. In fact drugs targeting heteromers with
high affinity would be safer as a given heteromer is only
expressed in very precise locations and the expected drug
doses should be smaller than current ones.
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